Adult Brain Tumor Clinical Trials
Questions about patients' participation in the following clinical trials can be directed to Jane Rabbitt or Margaretta Page by calling 415.353.2966, or by email to Valerie Kivett at kivettv@neurosurg.ucsf.edu.
Newly Diagnosed Malignant Glioma
A Phase II study of Bevacizumab (Avastin)plus Temodar and Tarceva during and after Radiation Therapy in patients with newly diagnosed Glioblastoma or Gliosarcoma
A Phase II Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme
Phase II, single-arm, open-label investigation of HSPPC-96 vaccine with concurrent temozolomide in patients with newly diagnosed glioblastoma multiforme
Newly Diagnosed Low-Grade Glioma
A Phase I Study of Temozolomide (SCH 52365) in the Treatment of Adult Patients with Supratentorial Low-Grade Glioma
Recurrent Tumor
A Phase I trial of Nanoliposomal CPT-11 (NL CPT-11)in Patients with Recurrent High-Grade Gliomas
ABTC04-03 - A Phase I Study of Vorinostat (SAHA) and Temozolomide in Patients with Malignant Glioma
Phase I/II trial of Oncophage (Heat Shock Protein Peptide Complex-96) Vaccine For Patients With Recurrent High Grade Glioma
ABTC05-02 - Phase I/II Studies of BAY 43-9006 (sorafenib) in Combination with OSI-774 (erlotinib), R115777 (tipifarnib) or CCI-779 (temsirolimus) in Patients with Recurrent Glioblastoma Multiforme or Gliosarcoma
ABTC07-01 - Phase I Trial of Aflibercept (VEGF Trap) with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients with Malignant Glioma
Phase II Study Of 7 Days On/7 Days Off Temozolomide In Patients With High-Grade Glioma
Phase II Trial of RAD001 in Patients with Recurrent Low-Grade Glioma
A Phase 2 Study of XL184 in Subjects with Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse
Non-Chemotherapy Protocols
San Francisco Bay Area Adult Glioma Prognosis Study
A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas
Adult Clinical Trials In Development
A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma
A Phase I Ascending Dose Trial of the safety and Tolerability of Toca-511 in Patients with Recurrent Glioblastoma Multiforme
A Phase I Study of MK-0752, a Notch Inhibitor, in Patients With Metastatic or Locally Advanced Breast Cancer and Other Solid Tumors